Details for New Drug Application (NDA): 020981

✉ Email this page to a colleague

NDA 020981 describes HYCAMTIN, which is a drug marketed by Sandoz and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the HYCAMTIN profile page.

The generic ingredient in HYCAMTIN is topotecan hydrochloride. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

Summary for 020981

Tradename:	HYCAMTIN
Applicant:	Sandoz
Ingredient:	topotecan hydrochloride
Patents:	1

Pharmacology for NDA: 020981

Mechanism of Action	Topoisomerase Inhibitors

Medical Subject Heading (MeSH) Categories for 020981

Topoisomerase I Inhibitors

Suppliers and Packaging for NDA: 020981

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981	NDA	Novartis Pharmaceuticals Corporation	0078-0672	0078-0672-01	10 CAPSULE in 1 BOTTLE (0078-0672-01)
HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981	NDA	Novartis Pharmaceuticals Corporation	0078-0673	0078-0673-01	10 CAPSULE in 1 BOTTLE (0078-0673-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 0.25MG BASE
Approval Date:	Oct 11, 2007	TE:		RLD:	Yes
Patent:	⤷ Subscribe	Patent Expiration:	Dec 10, 2024	Product Flag?	Y	Substance Flag?		Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 1MG BASE
Approval Date:	Oct 11, 2007	TE:		RLD:	Yes
Patent:	⤷ Subscribe	Patent Expiration:	Dec 10, 2024	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 020981

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007	⤷ Subscribe	⤷ Subscribe
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007	⤷ Subscribe	⤷ Subscribe
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007	⤷ Subscribe	⤷ Subscribe
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.